about
Purinergic signalling and cancerThrombosis in multiple myelomaVenous access catheter-related thrombosis in patients with cancer.Effect of comorbidity on risk of venous thromboembolism in patients with renal cell carcinomaThe prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trialThrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer.Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinomaClinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection.Identification of carboxyl terminal peptide of Fibrinogen as a potential serum biomarker for gastric cancer.The heparins and cancer: review of clinical trials and biological properties.Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort.Routine Hemostasis and Hemogram Parameters: Valuable Assessments for Coagulation Disorder and Chemotherapy in Cancer Patients.A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancerThe phospholipid code: a key component of dying cell recognition, tumor progression and host-microbe interactionsVenous Thromboembolism in Patients Diagnosed With Lung Cancer.Evaluation of thromboembolic events in cancer patients receiving bevacizumab according to the Japanese Adverse Drug Event Report database.Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as predictors of wound healing failure in head and neck reconstruction.The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma.A 47-year-old man with mesothelioma and neck swelling.Characterization of the cell-surface procoagulant activity of T-lymphoblastoid cell lines.APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.Retrospective Proteomic Analysis of a Novel, Cancer Metastasis-Promoting RGD-Containing Peptide.Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study.Low molecular weight heparin administration in cancer patients with hypercoagulability-related complications and carrying brain metastases: a case series study.Central venous access in oncology: ESMO Clinical Practice Guidelines.The elevated pre-operative plasma fibrinogen level is an independent negative prognostic factor for cancer-specific, disease-free and overall survival in soft-tissue sarcoma patients.Expression of coagulation factors and their receptors in tumor tissue and coagulation factor upregulation in peripheral blood of patients with cerebral carcinoma metastases.Analysis of haemostasis biomarkers in patients with advanced stage lung cancer during hypofractionated radiotherapy treatment.Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer.Prognostic significance of pretreatment plasma fibrinogen in patients with hepatocellular and pancreatic carcinomas: A meta-analysis.
P2860
Q24618782-D09E5607-2060-4414-877E-13FB8C3CA02CQ28219961-E9510D02-73F7-4340-8B5A-556FA68EB351Q33408419-AE7822D6-DD54-4375-B0E1-E9AFDC8425C8Q33598072-BCA58E51-0267-4DD8-AE3C-BC0AEF3D1562Q33747342-CD93CF5C-84F4-4C5F-B3C4-2C8C567C68F5Q33769516-3AD7CDCB-8424-4BFD-8B97-A5AE79BB694BQ34250240-DA5EF716-D3E7-40B0-829E-75B541BFBD08Q34441622-8D63829B-0A69-4279-92C3-31BAB9652FEBQ34538364-381F87D3-6960-42CB-A9D2-AD617C309172Q35534333-C629393D-EB29-4070-ACCC-D5347CB41772Q35808697-2BE29FB0-F26F-42BB-8379-F5470260DEBBQ35867858-2274FFCE-2025-4291-A656-14AE77042A7EQ36021780-3BE7F7F6-E754-43A2-A993-752365CF23C5Q36472966-9FB5F68E-9EC2-45F0-8422-800D366E8960Q37157888-BB209555-8A22-4BB9-B95C-D7097666CA3FQ37630295-B0A176F0-4C0E-4D80-AA04-77B12A682C36Q38602808-D0B72096-3115-469C-B811-567AE6965C41Q38944457-B922BEED-C447-43E9-B8D4-D7BB55D9EA9FQ39179354-2D51BEF9-3FD4-4334-8A45-288541A0EFB4Q39461515-B10873FB-1AA7-452D-B135-8A8040C2AEF1Q40235024-77922E5E-AFE4-44F0-8BFF-C303E6852A17Q40526636-72B1A3C9-729E-4FF8-8DC8-EFE059FB66E9Q40580716-686A592A-5C3A-438F-B025-D1279EB1B78EQ41877140-EC34F851-A963-4C69-8A39-CA16BB8E5CE7Q43235061-387911E5-BD33-4A73-A98A-D810B0057CC7Q43621266-572A652C-8E72-4A4D-BA8B-1F1FD24FE002Q44197966-75879089-DE8C-4E2A-B1A6-8B4D6205C243Q51792973-6707CF36-D8F7-4C14-8CAD-1B235A2A160EQ53086754-104915D0-FC7A-485F-AB47-C963EED3058BQ53747238-77A0334D-C40C-411E-B8E6-10DF7B0CE399Q55047973-D02DEE48-7CA0-42CC-9D27-5986865B8A7AQ55279779-ABB2BEFE-09DA-4672-9CF9-EE9A82733DC2Q55431114-9EB20E68-1871-4426-83C6-19B3EDD26A2A
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The thrombophilic state in cancer patients.
@ast
The thrombophilic state in cancer patients.
@en
The thrombophilic state in cancer patients.
@nl
type
label
The thrombophilic state in cancer patients.
@ast
The thrombophilic state in cancer patients.
@en
The thrombophilic state in cancer patients.
@nl
prefLabel
The thrombophilic state in cancer patients.
@ast
The thrombophilic state in cancer patients.
@en
The thrombophilic state in cancer patients.
@nl
P2093
P356
P1433
P1476
The thrombophilic state in cancer patients.
@en
P2093
Gouin-Thibault I
P356
10.1159/000046587
P577
2001-01-01T00:00:00Z